These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36812441)

  • 1. Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone.
    de Castro LF; Michel Z; Pan K; Taylor J; Szymczuk V; Paravastu S; Saboury B; Papadakis GZ; Li X; Milligan K; Boyce B; Paul SM; Collins MT; Boyce AM
    N Engl J Med; 2023 Feb; 388(8):766-768. PubMed ID: 36812441
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment with denosumab for pelvic fibrous dysplasia: A case report and review of the literature.
    Ikuta K; Sakai T; Koike H; Ito K; Imagama S; Nishida Y
    Medicine (Baltimore); 2021 Dec; 100(49):e28138. PubMed ID: 34889277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab for Fibrous Dysplasia: Promising, but Questions Remain.
    Collins MT; de Castro LF; Boyce AM
    J Clin Endocrinol Metab; 2020 Nov; 105(11):e4179-80. PubMed ID: 32478399
    [No Abstract]   [Full Text] [Related]  

  • 4. Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia-Risks and Benefits.
    Pan KS; Boyce AM
    Curr Osteoporos Rep; 2021 Apr; 19(2):141-150. PubMed ID: 33616817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter regarding - Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
    Theodorou DJ; Theodorou SJ; Tzimas V; Korompilias AV
    Bone; 2023 Oct; 175():116853. PubMed ID: 37473932
    [No Abstract]   [Full Text] [Related]  

  • 6. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases.
    Ganda K; Seibel MJ
    Osteoporos Int; 2014 Feb; 25(2):777-82. PubMed ID: 24311113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab Use in Adults With Fibrous Dysplasia: Case Reports and Review of the Literature.
    Hung C; Shibli-Rahhal A
    Endocr Pract; 2022 Nov; 28(11):1196-1201. PubMed ID: 35952985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrous dysplasia. Clinical review and therapeutic management.
    Florez H; Peris P; Guañabens N
    Med Clin (Barc); 2016 Dec; 147(12):547-553. PubMed ID: 27765282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of fibrous dysplasia: focus on denosumab.
    Huzum B; Antoniu S; Dragomir R
    Expert Opin Biol Ther; 2022 Mar; 22(3):397-405. PubMed ID: 34964677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of recalcitrant fibrous dysplasia treated with denosumab.
    Gautam KP; Rajan R; Cherian KE; Kapoor N; Hephzibah J; Paul TV
    Joint Bone Spine; 2020 Jul; 87(4):369-370. PubMed ID: 32279999
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.
    Rotman M; Hamdy NAT; Appelman-Dijkstra NM
    Br J Clin Pharmacol; 2019 Jun; 85(6):1169-1179. PubMed ID: 30471134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate therapy for fibrous dysplasia.
    DiMeglio LA
    Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
    van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bisphosphonates in the therapy of fibrous dysplasia. Relevant data and practical aspects].
    Egner-Höbarth S; Welkerling H; Windhager R
    Orthopade; 2007 Feb; 36(2):124, 126-30. PubMed ID: 17277960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects.
    Raborn LN; Burke AB; Ebb DH; Collins MT; Kaban LB; Boyce AM
    Osteoporos Int; 2021 Sep; 32(9):1889-1893. PubMed ID: 33772327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous Bisphosphonate Therapy as a Rescue Analgesic in Refractory Fibrous Dysplasia.
    Hatcher L; Henry N; Hooten WM; D'Souza RS
    Pain Med; 2022 Dec; 23(12):2085-2089. PubMed ID: 35652736
    [No Abstract]   [Full Text] [Related]  

  • 17. Denosumab treatment for fibrous dysplasia.
    Boyce AM; Chong WH; Yao J; Gafni RI; Kelly MH; Chamberlain CE; Bassim C; Cherman N; Ellsworth M; Kasa-Vubu JZ; Farley FA; Molinolo AA; Bhattacharyya N; Collins MT
    J Bone Miner Res; 2012 Jul; 27(7):1462-70. PubMed ID: 22431375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
    Trojani MC; Gensburger D; Bagouet F; Cortet B; Couture G; Marcelli C; Mehsen Cetre N; Breuil V; Chapurlat R
    Bone; 2023 Sep; 174():116819. PubMed ID: 37301527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spanish Menopause Society position statement: Use of denosumab in postmenopausal women.
    Cano A; Silvan JM; Estévez A; Baró F; Villero J; Quereda F; Ferrer J; Mendoza N; Sánchez-Borrego R;
    Maturitas; 2014 Sep; 79(1):117-21. PubMed ID: 25042873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab in the treatment of glucocorticoid-induced osteoporosis.
    Coskun Benlidayi I
    Rheumatol Int; 2018 Nov; 38(11):1975-1984. PubMed ID: 30019224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.